simendan has been researched along with dobutamine in 148 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.35) | 18.2507 |
| 2000's | 73 (49.32) | 29.6817 |
| 2010's | 58 (39.19) | 24.3611 |
| 2020's | 15 (10.14) | 2.80 |
| Authors | Studies |
|---|---|
| Akkila, J; Knuuti, MJ; Lehikoinen, P; Lehtonen, L; Någren, K; Saraste, M; Ukkonen, H; Voipio-Pulkki, LM | 1 |
| Du Toit, EF; McCarthy, J; Muller, CA; Opie, LH | 1 |
| Abdalla, M; Cleland, JG; Follath, F; Harjola, VP; Just, H; Lehtonen, L; Mitrovic, V; Papp, JG; Peuhkurinen, K; Sandell, EP; Scholz, H | 1 |
| Apajasalo, M; Cleland, JG; Kobelt, G; Takala, A; Zethraeus, N | 1 |
| Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM | 1 |
| Gronda, E; Mangiavacchi, M | 1 |
| Nieminen, MS | 1 |
| Boldt, J; Kirchner, J; Lehmann, A | 1 |
| Follath, F | 1 |
| Anifantakis, A; Athanassopoulos, G; Chatzigeorgiou, G; Cokkinos, DV; Iakovis, P; Karatasakis, G; Koutsogiannis, N; Manginas, A; Maounis, T; Papadakis, M; Spargias, KS | 1 |
| De Santis, V; Mazzesi, G; Miraldi, F; Ozdem, SS; Papalia, U; Puddu, PE; Tritapepe, L; Usta, C; Vitale, D | 1 |
| Agrios, N; Anastasiou-Nana, MI; Christodoulou, K; Dalianis, A; Kanakakis, J; Nanas, JN; Papazoglou, PP; Terrovitis, JV; Tsagalou, EP; Tsolakis, E | 1 |
| Bornstein, SR; Fournell, A; Picker, O; Scheeren, TW; Schwarte, LA | 1 |
| Coopersmith, CM | 1 |
| Huang, L; Sun, S; Tang, W; Wang, J; Weil, MH | 1 |
| Ayoub, IM; Gazmuri, RJ; Kolarova, JD | 1 |
| Alexopoulos, GP; Anastasiou-Nana, MI; Kanakakis, J; Nanas, JN; Nanas, SN; Ntalianis, A; Papazoglou, P; Terrovitis, JV; Tsagalou, EP; Tsolakis, E | 1 |
| Andreadou, I; Androulakis, A; Avgeropoulou, C; Demopoulou, M; Kallikazaros, I; Markantonis-Kyroudis, S; Missovoulos, P | 1 |
| Barretto, AC; Canaviera, R; Follador, W; Martins, ML; Oliveira, MT; Scipioni, A; Tsuji, RL | 1 |
| Reingardiene, D | 1 |
| Barraud, D; Mebazaa, A; Welschbillig, S | 1 |
| Cammarata, G; Cao, L; Huang, L; Sun, S; Tang, W; Weil, MH | 1 |
| Camara, AK; Chen, Q; Pagel, PS; Rhodes, SS; Riess, ML; Ropella, KM; Stowe, DF | 1 |
| Abreu-González, P; Domínguez-Rodríguez, A; Ferrer-Hita, JJ; García-González, MJ; Muñoz, MB | 1 |
| Atar, D; Hodt, A; Steine, K | 1 |
| Martos Fernández de Córdoba, F | 1 |
| Alvarez, J; Bouzada, M; Caruezo, V; Fernández, AL; García-Bengoechea, JB; Ginesta, V; González-Juanatey, JR; Rodríguez, J; Rubio, J; Taboada, M | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, GS; Gheorghiade, M; Iliodromitis, EK; Karatzas, D; Kremastinos, DT; Paraskevaidis, I; Parissis, JT; Tsiapras, D | 1 |
| Hennersdorf, M; Müller, K; Peters, A; Strauer, BE; Zeus, T | 1 |
| Brimioulle, S; Demester, JP; Fesler, P; Huez, S; Kerbaul, F; Naeije, R; Rondelet, B | 1 |
| Barán, M; Canales, HS; Dubin, A; Edul, VS; Estenssoro, E; Etcheverry, G; Maskin, B; Murias, G; Pozo, MO; Sottile, JP | 1 |
| Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
| Cavusoglu, Y | 1 |
| Pagel, PS | 1 |
| Cromheecke, S; De Hert, SG; Lorsomradee, S; Van der Linden, PJ | 1 |
| Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S | 1 |
| Erdem, A; Karadas, F; Tandogan, I; Yilmaz, MB | 1 |
| Cohen-Solal, A; Kivikko, M; Kleber, FX; Mebazaa, A; Nieminen, MS; Packer, M; Padley, RJ; Pocock, SJ; Põder, P; Thakkar, R | 1 |
| Farmakis, D; Nieminen, M; Parissis, JT | 1 |
| Kajimoto, K; Kawana, M; Watanabe, H | 1 |
| Auriti, A; Cianfrocca, C; Guido, V; Li, X; Mercuro, G; Pasceri, V; Pelliccia, F; Richichi, G; Santini, M | 1 |
| Abreu-González, P; Domínguez-Rodríguez, A; García-González, MJ; Samimi-Fard, S | 2 |
| Butler, J; Giamouzis, G; Giannakoulas, G | 1 |
| Ata, N; Birdane, A; Cavusoglu, Y; Demirustu, C; Gorenek, B; Tek, M; Timuralp, B; Unalir, A | 1 |
| Buerke, M; Buerke, U; Carter, JM; Christoph, A; Lemm, H; Prondzinsky, R; Reith, S; Russ, MA; Schlitt, A; Söffker, G; Swyter, M; Wegener, N; Werdan, K; Winkler, M | 1 |
| Akilli, A; Akin, M; Duygu, H; Ergene, O; Nalbantgil, S; Nazli, C; Ozerkan, F; Yildiz, A; Zoghi, M | 1 |
| Erdem, A; Karadas, F; Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB; Yontar, C | 2 |
| Banfor, PN; Campbell, TJ; Cox, BF; Fryer, RM; Marsh, KC; Polakowski, JS; Preusser, LC; Reinhart, GA | 1 |
| Damman, K; Voors, AA | 1 |
| Fryer, RM; Marsh, KC; Polakowski, JS; Segreti, JA | 1 |
| Auriti, A; Cianfrocca, C; Guido, V; Mercuro, G; Pasceri, V; Pelliccia, F; Santini, M | 1 |
| Blanco, N; Botbol, AL; Degrange, MA; del Mazo, CD; Levin, RL; Porcile, R; Salvagio, F; Tanus, E | 1 |
| Agha, SA; Butler, J; Georgiopoulou, V; Giamouzis, G; Giannakoulas, G; Kalogeropoulos, A; Karvounis, H; Tsarpalis, K | 1 |
| Celik, T; Iyisoy, A; Kardesoglu, E; Yuksel, UC | 1 |
| Anastasiou-Nana, M; Dimopoulos, S; Gerovasili, V; Kaldara, E; Kourtidou, S; Nanas, J; Nanas, S; Pierrakos, C; Roussos, C; Sarafoglou, S; Venetsanakos, J | 1 |
| Akyuz, S; Alioglu, E; Bozkaya, YT; Duygu, H; Gunduz, R; Kirilmaz, B; Ozdogan, O; Payzin, S; Turk, U; Turkoglu, C | 1 |
| Bistola, V; Filippatos, G; Ikonomidis, I; Kremastinos, DT; Papadopoulos, C; Paraskevaidis, IA; Parissis, JT | 1 |
| González-Costello, J; Homs, S | 1 |
| Aydede, H; Erbüyün, K; Erhan, Y; Ok, G; Tekin, I; Tok, D; Türköz, E; Vatansever, S | 1 |
| Akilli, A; Akin, M; Duygu, H; Ergene, O; Erturk, U; Nalbantgil, S; Nazli, C; Ozerkan, F; Zoghi, M | 1 |
| Mebazaa, A; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P | 1 |
| Cleland, JG; Cohen-Solal, A; Filippatos, GS; Huang, B; Mebazaa, A; Nieminen, MS; Padley, RJ; Salon, JE; Thakkar, R | 1 |
| Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C | 1 |
| Akilli, A; Akin, M; Duygu, H; Nalbantgil, S; Ozerkan, F; Yildiz, A; Zoghi, M | 1 |
| Baumert, JH; Hein, M; Roehl, AB; Rossaint, R; Scherer, K; Steendijk, P | 1 |
| Chay Woodward, T; de Lissovoy, G; Fraeman, K; Salon, J; Sterz, R | 1 |
| Cai, D; Cohen-Solal, A; Huang, B; Logeart, D; Mebazaa, A; Nieminen, MS | 1 |
| Abdullah, GM; Alhashemi, JA; Alotaibi, QA; Shalabi, SA | 1 |
| Ackermann, D; Grottke, O; Hein, M; Rieg, AD; Rossaint, R; Schälte, G; Schroth, SC | 1 |
| Blomquist, S; Cunha-Goncalves, D; Larsson, A; Perez-de-Sa, V; Thörne, J | 1 |
| Kiviniemi, V; Kurola, J; Leppikangas, H; Lindgren, L; Ruokonen, E; Rutanen, J | 1 |
| Bilgehan, K; Duman, D; Palit, F; Sacide, A; Simsek, E | 1 |
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
| Yalta, K; Yilmaz, MB; Yontar, OC | 2 |
| Geilfus, D; Graf, BM; Missler, G; Sinner, B; Zausig, YA; Zink, W | 1 |
| Hermansen, SE; How, OJ; Jakobsen, Ø; Müller, S; Myrmel, T; Røsner, A; Stenberg, TA | 1 |
| Omerovic, E; Swedberg, K; Waagstein, F | 1 |
| Andersson, B; Bergh, CH; Dahlström, U; Forfang, K; Kivikko, M; Sarapohja, T; Ullman, B; Wikström, G | 1 |
| Abroug, F; Dachraoui, F; Dimassi, S; Mebazaa, A; Ouanes, I; Ouanes-Besbes, L | 1 |
| Alexander, PM; Butt, WW; Penny, DJ; Ryerson, LM; Shann, FA; Shekerdemian, LS | 1 |
| Campia, U; Gheorghiade, M; Nodari, S | 1 |
| Wikström, BG | 1 |
| Ayub-Ferreira, SM; Bacal, F; Bocchi, EA; Mangini, S; Marcondes-Braga, FG | 1 |
| Cui, L; Hao, YM; Jiang, DJ; Li, GP; Li, HM; Liu, J; Qi, GX; Wang, L; Wang, WZ; Wei, JP; Zhang, YD | 1 |
| Erdem, A; Tandogan, I; Yalta, K; Yilmaz, MB; Yontar, OC | 1 |
| Anastasiou-Nana, M; Bistola, V; Ikonomidis, I; Papadopoulos, C; Paraskevaidis, IA; Parissis, J; Stassinos, V | 1 |
| Ata, N; Birdane, A; Cavuşoğlu, Y; Demirüstü, C; Göktekin, Ö; Görenek, B; Tek, M; Ünalır, A | 1 |
| Böhm, M; Cai, D; Cohen Solal, A; Filippatos, GS; Huang, B; Kivikko, M; Link, A; Mebazaa, A; Nieminen, MS; Padley, RJ; Salem, R | 1 |
| Bettari, L; Bugatti, S; Carubelli, V; Danesi, R; Dei Cas, L; Lazzarini, V; Lombardi, C; Metra, M; Monti, A; Villa, C | 1 |
| Brasolin, B; Bruno, N; Caira, C; D'Ambrosi, A; Fedele, F; Mancone, M | 1 |
| Läer, S; Vogt, W | 1 |
| Inal, MT; Memiş, D; Sut, N | 1 |
| Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V | 1 |
| Borlu, F; Dal, MS; Oztekin, E; Paksoy, F; Tursun, I; Ulaş, T | 1 |
| Fournell, A; Picker, O; Scheeren, TW; Schwarte, LA | 1 |
| Noori, S; Seri, I | 1 |
| An, T; Huang, Y; Lü, R; Qing, EM; Qing, P; Wei, BQ; Zhang, J; Zhang, YH; Zhou, Q; Zou, CH | 1 |
| Bai, XJ; Huang, Y; Jiang, YN; Li, H; Liu, WX; Qing, EM; Qu, P; Sun, YX; Wei, BQ; Zhang, J; Zhang, L; Zhang, YH; Zhou, Q | 1 |
| Amir, O; Zafrir, B | 1 |
| Cai, D; Cohen-Solal, A; Deye, N; Kivikko, M; Laribi, S; Laterre, PF; Mebazaa, A; Nikolaou, M; Parissis, J; Paugam-Burtz, C; Poder, P; Pohjanjousi, P; Seronde, MF; Yilmaz, MB | 1 |
| Ebade, AA; Khalil, MA; Mohamed, AK | 1 |
| Apajasalo, M; D'Ambrosi, A; Fedele, F; Lucioni, C; Mazzi, S; Pollesello, P | 1 |
| Huang, LQ; Huang, X; Jiang, RL; Lei, S; Xia, GL; Zhi, YH; Zhu, MF | 1 |
| Barrett, NA; Berry, WT; Hewson, RW; Langrish, CJ; McKenzie, CA | 1 |
| Barrett, CJ; Beil, M; Budgett, DM; Fu, F; Guild, SJ; Malpas, SC; McCormick, D; Rigel, DF; Stehlin, E; Whalley, G | 1 |
| Alvarez, J; Baluja, A; Caruezo, V; Castroagudin, J; Otero, P; Rial, M; Rodriguez, A; Rodriguez, I; Rodriguez, J; Selas, S; Taboada, M; Tome, S; Veiras, S | 1 |
| Bacaksiz, A; Erdogan, E; Ergelen, M; Erturk, M; Karakurt, H; Sonmez, O; Tasal, A; Turfan, M; Uyarel, H; Vatankulu, MA | 1 |
| Aleixandre, L; Cortell, J; Herrera, P; Loro, JM; Valera, F; Vicente, R | 1 |
| Buerke, M; Haerting, J; Hirsch, K; Prondzinsky, R; Thiele, H; Unverzagt, S; Wachsmuth, L; Werdan, K | 1 |
| Akturk, IF; Birant, A; Erturk, M; Karakurt, H; Kurtar Mansıroglu, A; Oner, E; Somuncu, MU; Uzun, F; Yalcin, AA; Yildirim, A | 1 |
| Chivite, D; Corbella, X; Formiga, F | 1 |
| Calabrò, MG; Covello, RD; Greco, M; Greco, T; Landoni, G; Morelli, A; Pasin, L; Zangrillo, A | 1 |
| Burkhardt, BE; Rücker, G; Stiller, B | 1 |
| Bignami, E; De Luca, M; Di Tomasso, N; Frau, G; Landoni, G; Likhvantsev, V; Lomivorotov, V; Monaco, F; Oriani, A; Putzu, A; Zangrillo, A | 1 |
| Çavuşoğlu, Y; Demirtaş, S; Gencer, E; Güneş, H; Kalaycı, S; Korkmaz, Ş; Mert, UK; Mutlu, F; Özdemir, S; Şaşmaz, H; Yılmaz, MB | 1 |
| Apajasalo, M; Bertranou, E; Heringlake, M; Kivikko, M; Mardiguian, S; Pollesello, P; Smare, C | 1 |
| Ertl, G; Pauschinger, M; von Scheidt, W | 1 |
| Harjola, VP; Kivikko, M; Nieminen, MS; Pollesello, P; Sarapohja, T; Tarvasmäki, T | 1 |
| Hu, MH; Ji, CL; Lai, ZZ; Meng, JB; Tian, S; Xu, XJ; Zhang, G | 1 |
| Angelini, GD; Belletti, A; Benedetto, U; Biondi-Zoccai, G; Landoni, G; Leggieri, C; Silvani, P; Zangrillo, A | 1 |
| Ferjani, M; Hajjej, Z; Labbene, I; Meddeb, B; Morelli, A; Sellami, W | 1 |
| Baidya, DK; Bhattacharjee, S; Maitra, S; Soni, KD | 1 |
| Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M | 1 |
| Almeida, I; Caetano, F; Costa, M; Fernandes, A; Gonçalves, L; Madeira, M; Reis, L | 1 |
| Frantz, S; Henrich, EC; Prondzinsky, R; Schumann, J; Strobl, H; Thiele, H; Unverzagt, S; Weiche, S; Werdan, K | 1 |
| Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA | 1 |
| Anker, SD; Balligand, JL; Bauersachs, J; Brutsaert, D; Carrier, L; Chlopicki, S; Cleland, JG; de Boer, RA; de Keulenaer, G; Dietl, A; Eschenhagen, T; Fischmeister, R; Hamdani, N; Harjola, VP; Heinzel, FR; Heymans, S; Hilfiker-Kleiner, D; Holzmeister, J; Limongelli, G; Linke, WA; Lund, LH; Lyon, AR; Maack, C; Manstein, DJ; Masip, J; Mebazaa, A; Metra, M; Metzger, J; Mueller, C; Papp, Z; Pieske, B; Ponikowski, P; Ristić, A; Ruschitzka, F; Seferović, PM; Skouri, H; Tocchetti, CG; Yilmaz, MB; Zimmermann, WH | 1 |
| Andersson, B; Bartfay, SE; Bergh, N; Bollano, E; Dahlberg, P; Gilljam, T; Hjalmarsson, C; Karason, K; Lannemyr, L; Ljungman, C; Ricksten, SE; Rundqvist, B | 1 |
| Dempsey, E; Rabe, H | 1 |
| Babik, B; Bayat, S; Fodor, GH; Habre, W; Peták, F | 1 |
| Araújo, I; Campos, L; Cunha, GJL; Fernandes, L; Ferraz, M; Fonseca, C; Gomes, RV; Morais, R; Rocha, BML | 1 |
| Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S | 1 |
| Bottio, T; Gerosa, G; Piperata, A | 1 |
| Efremov, L; Frantz, S; Mikolajczyk, R; Schumann, J; Sedding, D; Tongers, J; Uhlig, K | 1 |
| Filipiak, KJ; Gasecka, A; Jaguszewski, MJ; Szarpak, L | 1 |
| Alvarez, J; Bettex, D; Bouchez, S; Fruhwald, S; Girardis, M; Grossini, E; Guarracino, F; Heringlake, M; Herpain, A; Pollesello, P; Toller, W; Tritapepe, L | 1 |
| Filipiak, KJ; Gasecka, A; Jaguszewski, MJ; Szarpak, L; Targonski, R | 1 |
| Belletti, A; Cassina, T; Clivio, S; Putzu, A | 1 |
| Chen, J; Chen, WT; Lei, YY; Lin, XF; Liu, DH; Liu, YY; Ning, YL; Xian, SX; Yang, ZQ | 1 |
| Cheng, Q; Guo, J; Zhang, X; Zhu, Y | 1 |
| Hu, K; Mathew, R | 1 |
| Chen, N; Cui, N; Ding, XX; Li, N; Sun, T; Wang, SH; Yu, ZB; Zhang, N | 1 |
| Aydın, C; Kaplangoray, M | 1 |
| Fang, X; Huang, P; Jin, H; Liu, F; Ma, Z; Wang, S | 1 |
| Dong, N; Guo, Q; Lan, H; Li, C; Shi, J; Wang, G; Xiong, T; Zhang, J; Zheng, Q | 1 |
30 review(s) available for simendan and dobutamine
| Article | Year |
|---|---|
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents | 2003 |
[Inotropic agents in advanced and refractory heart failure].
Topics: Cardiotonic Agents; Dobutamine; Dopamine; Drug Administration Schedule; Heart Failure; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Treatment Failure; Treatment Outcome | 2003 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Ischemia; Pyridazines; Simendan | 2003 |
[The novelty in the treatment of heart failure].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Multicenter Studies as Topic; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan; Vasodilator Agents | 2005 |
Randomized clinical trials with levosimendan.
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome | 2005 |
[Medical and ventilatory treatment of acute heart failure].
Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Continuous Positive Airway Pressure; Diuretics; Dobutamine; Furosemide; Heart Failure; Humans; Hydrazones; Isosorbide Dinitrate; Natriuretic Agents; Natriuretic Peptide, Brain; Nitric Oxide Donors; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridazines; Simendan; Vasodilator Agents | 2006 |
The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Topics: Aged; Biological Availability; Calcium Channels; Cardiotonic Agents; Dobutamine; Half-Life; Heart Failure; Hospitalization; Humans; Hydrazones; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Tissue Distribution; Treatment Outcome | 2007 |
Classical inotropes and new cardiac enhancers.
Topics: Algorithms; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Hydrazones; Milrinone; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2007 |
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2007 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents.
Topics: Cardiotonic Agents; Cardiovascular System; Dobutamine; Dopamine; Epinephrine; Hemodynamics; Humans; Hydrazones; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Milrinone; Pyridazines; Shock; Simendan; Vasoconstrictor Agents; Vasopressins | 2012 |
Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Chronic Disease; Dobutamine; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hydrazones; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Pyridazines; Simendan | 2012 |
Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Comorbidity; Critical Illness; Dobutamine; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Hypotension; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Survival Rate; Treatment Outcome | 2013 |
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Enoximone; Humans; Hydrazones; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2014 |
[Organ-protection therapy. A new therapeutic approach for acute heart failure?].
Topics: Acute Disease; Amides; Benzazepines; Cardio-Renal Syndrome; Dobutamine; Fumarates; Heart Failure; Humans; Hydrazones; Inflammation; Kaplan-Meier Estimate; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Simendan; Therapies, Investigational; Tolvaptan | 2014 |
A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.
Topics: Bayes Theorem; Cardiac Surgical Procedures; Critical Illness; Dobutamine; Enoximone; Humans; Hydrazones; Milrinone; Pyridazines; Simendan; Vasodilator Agents | 2015 |
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Heart Defects, Congenital; Humans; Hydrazones; Infant; Infant, Newborn; Milrinone; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome; Time Factors | 2015 |
Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials.
Topics: Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan | 2015 |
Long-term intravenous inotropes in low-output terminal heart failure?
Topics: Administration, Intravenous; Cardiac Output; Cardiac Output, Low; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Drug Administration Schedule; Heart Failure; Heart Transplantation; Humans; Hydrazones; Milrinone; Odds Ratio; Practice Guidelines as Topic; Pyridazines; Risk Factors; Simendan; Time Factors; Treatment Outcome; Waiting Lists | 2016 |
The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
Topics: Arginine Vasopressin; Cardiotonic Agents; Dobutamine; Dopamine; Epinephrine; Humans; Hydrazones; Network Meta-Analysis; Norepinephrine; Odds Ratio; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan; Treatment Outcome; Vasoconstrictor Agents; Vasopressins | 2017 |
Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials.
Topics: Adult; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Intensive Care Units; Norepinephrine; Pyridazines; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic; Simendan | 2017 |
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2018 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defects, Congenital; Humans; Hypotension; Infant, Newborn; Intensive Care Units, Neonatal; Milrinone; Neonatal Sepsis; Norepinephrine; Persistent Fetal Circulation Syndrome; Shock; Simendan; Vasoconstrictor Agents; Vasopressins | 2019 |
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Topics: Aged; Disease Progression; Dobutamine; Dopamine; Epinephrine; Female; Hemodynamics; Humans; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Network Meta-Analysis; Norepinephrine; Patient Safety; Recombinant Proteins; Shock, Cardiogenic; Simendan; Treatment Outcome | 2020 |
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Epinephrine; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Placebos; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2020 |
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety.
Topics: Adrenergic beta-Antagonists; Cardiac Surgical Procedures; Cardiotonic Agents; Critical Care; Dobutamine; Heart Failure; Hemodynamics; Humans; Shock, Cardiogenic; Simendan | 2021 |
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2021 |
Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis.
Topics: Disease-Free Survival; Dobutamine; Heart Diseases; Lactic Acid; Sepsis; Simendan; Stroke Volume; Survival Rate | 2021 |
Inotrope and vasopressor use in cardiogenic shock: what, when and why?
Topics: Cardiotonic Agents; Dobutamine; Humans; Shock, Cardiogenic; Simendan; Vasoconstrictor Agents | 2022 |
A Meta-Analysis of the Effects of Levosimendan on Cardiac Function and Outcomes in Patients with Sepsis.
Topics: Dobutamine; Humans; Hydrazones; Pyridazines; Sepsis; Shock, Septic; Simendan; Stroke Volume; Ventricular Function, Left | 2023 |
47 trial(s) available for simendan and dobutamine
| Article | Year |
|---|---|
Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.
Topics: Adult; Calcium; Carbon Radioisotopes; Cardiotonic Agents; Chromatography, High Pressure Liquid; Dobutamine; Echocardiography; Epinephrine; Feasibility Studies; Heart; Hemodynamics; Humans; Hydrazones; Male; Myocardial Contraction; Myocardium; Nitroprusside; Norepinephrine; Oxygen Consumption; Pyridazines; Simendan; Sympathomimetics; Tomography, Emission-Computed; Vasodilation; Vasodilator Agents | 1997 |
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome | 2002 |
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Double-Blind Method; Europe; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Life Expectancy; Male; Middle Aged; Patient Admission; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome | 2003 |
Levosimendan compared with dobutamine in low output patients.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Double-Blind Method; Hemodynamics; Humans; Hydrazones; Pulmonary Wedge Pressure; Pyridazines; Simendan | 2003 |
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Topics: Adrenergic beta-Agonists; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Death, Sudden, Cardiac; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Morbidity; Myocardial Contraction; Pulmonary Wedge Pressure; Pyridazines; Risk Factors; Severity of Illness Index; Shock, Cardiogenic; Simendan; Stroke Volume; Survival Analysis; Time; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2003 |
Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Topics: Administration, Oral; Cardiac Output; Cardiotonic Agents; Diuretics; Dobutamine; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Simendan | 2004 |
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Output; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Infusions, Intravenous; Middle Aged; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Treatment Outcome | 2006 |
[Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery].
Topics: Aged; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Dobutamine; Female; Hemodynamics; Humans; Hydrazones; Male; Prospective Studies; Pyridazines; Simendan | 2006 |
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Topics: Aged; Apoptosis; Cardiotonic Agents; Chronic Disease; Dobutamine; Echocardiography; Fas Ligand Protein; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |
Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyridazines; Simendan; Single-Blind Method | 2008 |
The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
Topics: Adrenergic beta-Agonists; Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Administration Schedule; Drug Therapy, Combination; Elective Surgical Procedures; Female; Heart Diseases; Humans; Hydrazones; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2007 |
Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin.
Topics: Adult; Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Function, Left | 2008 |
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Analysis | 2007 |
Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography.
Topics: Cardiotonic Agents; Dobutamine; Echocardiography; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2007 |
Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiotonic Agents; Diastole; Dobutamine; Echocardiography, Doppler; Female; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Shock, Cardiogenic; Simendan; Ventricular Function, Left | 2008 |
Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.
Topics: Angioplasty, Balloon, Coronary; Cardiotonic Agents; Catecholamines; Dobutamine; Female; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Shock, Cardiogenic; Simendan | 2007 |
Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right | 2008 |
Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Male; Middle Aged; Pyridazines; Simendan; Urination | 2007 |
Strain rate analysis and levosimendan improve detection of myocardial viability by dobutamine echocardiography in patients with post-infarction left ventricular dysfunction: a pilot study.
Topics: Aged; Dobutamine; Drug Synergism; Echocardiography; Elasticity Imaging Techniques; Female; Humans; Hydrazones; Image Enhancement; Male; Myocardial Infarction; Pyridazines; Reproducibility of Results; Sensitivity and Specificity; Simendan; Ventricular Dysfunction, Left | 2008 |
[The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome].
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Prospective Studies; Pyridazines; Simendan | 2008 |
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Propanolamines; Pyridazines; Simendan; Time Factors; Treatment Outcome | 2008 |
Effects of levosimendan on left atrial functions in patients with ischemic heart failure.
Topics: Aged; Atrial Function, Left; Blood Pressure; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Ischemia; Pyridazines; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Pressure | 2008 |
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Cause of Death; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Survival Rate; Treatment Outcome | 2009 |
Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure.
Topics: Aged; Cardiotonic Agents; Diastole; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Stroke Volume; Systole; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function, Right | 2009 |
Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis.
Topics: Cardiotonic Agents; Dobutamine; Electrocardiography; Female; Humans; Hydrazones; Image Interpretation, Computer-Assisted; Injections, Intravenous; Male; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Pyridazines; Radiography; Simendan; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2009 |
The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Female; Health Expenditures; Heart Failure; Humans; Hydrazones; Length of Stay; Male; Middle Aged; Patient Admission; Pyridazines; Simendan | 2008 |
Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Topics: Adult; Aged; Aged, 80 and over; Atrial Function, Left; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Single-Blind Method; Treatment Outcome; Young Adult | 2009 |
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Antihypertensive Agents; Cardiotonic Agents; Confidence Intervals; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Odds Ratio; Perfusion; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vasodilator Agents | 2010 |
[Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome | 2010 |
Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure.
Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Dobutamine; Female; Heart Conduction System; Heart Failure; Humans; Hydrazones; Male; Muscle Contraction; Pyridazines; Simendan; Statistics, Nonparametric | 2010 |
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Dobutamine; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Parenteral; Male; Middle Aged; Pyridazines; Risk Factors; Simendan; Tachycardia, Ventricular; Ventricular Premature Complexes | 2010 |
Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiotonic Agents; Confidence Intervals; Dobutamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Patient Discharge; Proportional Hazards Models; Pyridazines; Reference Values; Risk Assessment; Severity of Illness Index; Simendan; Survival Analysis; Treatment Outcome | 2011 |
The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock.
Topics: Cardiotonic Agents; Coloring Agents; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hydrazones; Indocyanine Green; Liver Circulation; Liver Function Tests; Male; Metabolic Clearance Rate; Microcirculation; Middle Aged; Prospective Studies; Pyridazines; Regional Blood Flow; Shock, Septic; Simendan | 2012 |
[The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Topics: Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Prospective Studies; Pyridazines; Simendan; Treatment Outcome | 2012 |
[Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure].
Topics: Adolescent; Adult; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Young Adult | 2012 |
[Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure].
Topics: Aged; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome | 2012 |
Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.
Topics: Blood Pressure; Cardiac Output; Cardiac Surgical Procedures; Cardiotonic Agents; Child, Preschool; Dobutamine; Female; Humans; Hydrazones; Hypertension, Pulmonary; Infant; Male; Prospective Studies; Pulmonary Artery; Pyridazines; Simendan | 2013 |
A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study.
Topics: Aged; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Dobutamine; Female; Hemodynamics; Humans; Hydrazones; Liver Circulation; Male; Postoperative Complications; Pyridazines; Simendan; Vascular Resistance | 2013 |
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Pyridazines; Recovery of Function; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Turkey; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Serum Albumin; Serum Albumin, Human; Simendan; Treatment Outcome; Turkey; Young Adult | 2015 |
Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Dobutamine; Drug Therapy, Combination; Female; Finland; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Proportional Hazards Models; Pyridazines; Retrospective Studies; Simendan; Survival Analysis; Treatment Outcome | 2016 |
Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial.
Topics: Biomarkers; Demography; Dobutamine; Fatty Acid-Binding Proteins; Female; Hemodynamics; Humans; Hydrazones; Lactic Acid; Male; Middle Aged; Multivariate Analysis; Myocardium; Natriuretic Peptide, Brain; Pyridazines; Regression Analysis; Shock, Septic; Simendan; Troponin I; Ventricular Function, Left | 2016 |
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomized Controlled Pilot Study.
Topics: Adult; Aged; Dobutamine; Double-Blind Method; Humans; Hydrazones; Male; Middle Aged; Pilot Projects; Pyridazines; Shock, Septic; Simendan | 2017 |
Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
Topics: Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hemodynamic Monitoring; Hemodynamics; Humans; Male; Middle Aged; p-Aminohippuric Acid; Renal Circulation; Renal Insufficiency; Renal Plasma Flow; Simendan | 2018 |
Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy.
Topics: Cardiomyopathies; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Norepinephrine; Prospective Studies; Pyridazines; Sepsis; Shock, Septic; Simendan; Single-Blind Method; Stroke Volume; Ventricular Function, Left | 2023 |
71 other study(ies) available for simendan and dobutamine
| Article | Year |
|---|---|
Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Agonists; Calcium Channel Blockers; Cyclic AMP; Cyclic GMP; Dobutamine; Glyburide; Guinea Pigs; Heart; Hydrazones; In Vitro Techniques; L-Lactate Dehydrogenase; Lactic Acid; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nucleotides, Cyclic; Phosphocreatine; Pyridazines; Simendan; Stereoisomerism | 1999 |
Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Calcium Channels, L-Type; Cardiac Output, Low; Cardiotonic Agents; Diastole; Dobutamine; Dopamine; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Greece; Heart Failure; Heart Ventricles; Hematocrit; Hemoglobins; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Potassium; Pyridazines; Severity of Illness Index; Simendan; Stimulation, Chemical; Survival Analysis; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Artery Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electric Stimulation; Female; Heart Atria; Heart Valve Diseases; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Pyridazines; Rheumatic Heart Disease; Rolipram; Simendan; Troponin C | 2004 |
Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs.
Topics: Adrenergic beta-Agonists; Animals; Cardiotonic Agents; Dobutamine; Dogs; Female; Gastric Mucosa; Hemodynamics; Hydrazones; Male; Microcirculation; Milrinone; Oxygen; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents | 2005 |
Levosimendan and gut mucosal blood flow--not all inotropes are created equal.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Gastric Mucosa; Hemoglobinometry; Hydrazones; Microcirculation; Milrinone; Oxygen Consumption; Pyridazines; Simendan; Vasodilator Agents | 2005 |
Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction.
Topics: Analysis of Variance; Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Cardiotonic Agents; Dobutamine; Heart Arrest; Hydrazones; Male; Myocardial Stunning; Prospective Studies; Pyridazines; Random Allocation; Simendan; Swine | 2005 |
Inotropic options for postresuscitation myocardial dysfunction.
Topics: Animals; Cardiomyopathies; Cardiopulmonary Resuscitation; Cardiotonic Agents; Dobutamine; Heart Arrest; Humans; Hydrazones; Myocardial Stunning; Pyridazines; Simendan; Swine | 2005 |
Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Pyridazines; Radionuclide Ventriculography; Risk; Simendan; Survival Rate | 2005 |
[Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Health Care Costs; Heart Failure; Hospital Costs; Humans; Hydrazones; Length of Stay; Pyridazines; Simendan | 2005 |
Levosimendan improves postresuscitation outcomes in a rat model of CPR.
Topics: Adrenergic beta-Agonists; Animals; Cardiac Output; Cardiopulmonary Resuscitation; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Heart Arrest; Heart Rate; Hydrazones; Male; Pyridazines; Random Allocation; Rats; Rats, Sprague-Dawley; Simendan; Single-Blind Method; Survival Rate; Ventricular Fibrillation; Ventricular Function, Left | 2005 |
Ischemia-reperfusion injury changes the dynamics of Ca2+-contraction coupling due to inotropic drugs in isolated hearts.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Digoxin; Dobutamine; Dopamine; Dopamine Agonists; Feedback, Physiological; Guinea Pigs; Heart; Hydrazones; In Vitro Techniques; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; Pyridazines; Signal Transduction; Simendan; Ventricular Function, Left | 2006 |
[On levosimendan in comparison with dobutamine].
Topics: Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Pyridazines; Simendan | 2006 |
[Therapy of acute decompensated heart failure with levosimendan].
Topics: Adult; Aged; Calcium Channel Agonists; Cardiotonic Agents; Conscious Sedation; Critical Care; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Norepinephrine; Pyridazines; Shock, Cardiogenic; Simendan | 2006 |
Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Heart Failure; Hydrazones; Hypertension, Pulmonary; Prospective Studies; Pulmonary Artery; Pulmonary Circulation; Pyridazines; Random Allocation; Simendan; Ventricular Dysfunction, Right | 2006 |
Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study.
Topics: Acidosis; Analysis of Variance; Animals; Cardiotonic Agents; Dobutamine; Endotoxemia; Hydrazones; Lactic Acid; Oxygen; Prospective Studies; Pyridazines; Random Allocation; Sheep; Shock, Septic; Simendan; Splanchnic Circulation | 2007 |
Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
Topics: Adrenergic beta-Agonists; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Humans; Hydrazones; Milrinone; Myocardial Contraction; Perioperative Care; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones; Lipopolysaccharides; Milrinone; Pyridazines; Rabbits; Sepsis; Simendan; Systole; Ventricular Function, Left | 2007 |
A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2007 |
Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.
Topics: Dobutamine; Humans; Hydrazones; Natriuretic Peptide, Brain; Neurotransmitter Agents; Peptide Fragments; Protein Precursors; Pyridazines; Simendan; Treatment Outcome | 2008 |
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
Topics: Acetamides; Animals; Blood Pressure; Calcium; Cardiac Output; Cardiotonic Agents; Cardiovascular System; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Rate; Hydrazones; Male; Milrinone; Myocardial Contraction; Oxygen Consumption; Potassium; Potassium Channels; Pulmonary Circulation; Pyridazines; Simendan; Time Factors; Vascular Resistance; Vasodilator Agents; Ventricular Function, Left | 2008 |
Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al."
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Glomerular Filtration Rate; Heart Failure; Humans; Hydrazones; Kidney; Pyridazines; Simendan | 2007 |
Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and m
Topics: Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Cardiovascular Physiological Phenomena; Dobutamine; Drug Combinations; Heart Rate; Hemodynamics; Hydrazones; Male; Milrinone; Myocardial Contraction; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Vascular Resistance | 2008 |
Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure.
Topics: Adrenergic beta-Agonists; Brachial Artery; Cardiotonic Agents; Case-Control Studies; Chronic Disease; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Myocardial Reperfusion; Oxygen Consumption; Prognosis; Prospective Studies; Pyridazines; Simendan; Spectroscopy, Near-Infrared; Vasodilator Agents | 2008 |
Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Stress; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume | 2008 |
[Superiority of levosimendan to dobutamine in postoperative low cardiac output syndrome: is it due to previous beta-blocker treatment?].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiac Output, Low; Dobutamine; Drug Interactions; Humans; Hydrazones; Length of Stay; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2008 |
Effects of levosimendan and dobutamine on experimental acute lung injury in rats.
Topics: Acute Lung Injury; Animals; Cardiotonic Agents; Dobutamine; Hydrazones; Hypertension; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-1beta; Lung; Male; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyridazines; Rats; Rats, Wistar; Simendan; Tumor Necrosis Factor-alpha | 2009 |
Levosimendan: from basic science to clinical practice.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Kidney; Myocardial Contraction; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Quality of Life; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2009 |
Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2009 |
Anti-ischemic effects of inotropic agents in experimental right ventricular infarction.
Topics: Animals; Blood Gas Analysis; Cardiotonic Agents; Dobutamine; Female; Heart Ventricles; Hemodynamics; Hydrazones; Inflammation Mediators; Milrinone; Myocardial Infarction; Myocardial Ischemia; Myocarditis; Myocardium; Myoglobin; Neutrophil Infiltration; Pyridazines; Simendan; Swine; Troponin T | 2009 |
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan | 2009 |
Levosimendan vs dobutamine in septic shock.
Topics: APACHE; Cardiotonic Agents; Dobutamine; Humans; Hydrazones; Lactic Acid; Pyridazines; Randomized Controlled Trials as Topic; Shock, Septic; Simendan | 2009 |
Influence of temperature on the positive inotropic effect of levosimendan, dobutamine and milrinone.
Topics: Animals; Calcium; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Female; Guinea Pigs; Hydrazones; Hypothermia; In Vitro Techniques; Milrinone; Myocardial Contraction; Pyridazines; Random Allocation; Simendan; Temperature | 2009 |
Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine.
Topics: Animals; Blood Pressure; Blood Volume; Cardiac Output; Cardiotonic Agents; Combined Modality Therapy; Disease Models, Animal; Dobutamine; Drug Therapy, Combination; Fluid Therapy; Heart Rate; Hemodynamics; Hydrazones; Hypotension; Lactic Acid; Lipopolysaccharides; Liver Circulation; Norepinephrine; Oxygen; Pyridazines; Regional Blood Flow; Shock, Septic; Simendan; Splanchnic Circulation; Swine; Time Factors; Vascular Resistance | 2009 |
Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Double-Blind Method; Drug Overdose; Heart Failure; Hemodynamics; Hydrazones; Propranolol; Pyridazines; Random Allocation; Simendan; Survival Analysis; Swine | 2009 |
Levosimendan in acute and chronic right ventricle failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Dobutamine; Hemodynamics; Humans; Hydrazones; Pyridazines; Simendan; Ventricular Dysfunction, Right | 2010 |
Direct cardiac effects of dobutamine, dopamine, epinephrine, and levosimendan in isolated septic rat hearts.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dopamine; Dose-Response Relationship, Drug; Epinephrine; Heart; Heart Rate; Hydrazones; In Vitro Techniques; Male; Models, Animal; Myocardium; Oxygen Consumption; Peritonitis; Pyridazines; Random Allocation; Rats; Rats, Wistar; Shock, Septic; Simendan; Therapeutic Equivalency | 2010 |
Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan.
Topics: Analysis of Variance; Animals; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Hydrazones; Male; Myocardial Contraction; Myocardial Stunning; Oxygen Consumption; Pyridazines; Simendan; Swine | 2010 |
Superiority of levosimendan over dobutamine in right ventricle failure.
Topics: Cardiotonic Agents; Critical Care; Critical Illness; Dobutamine; Female; Heart Function Tests; Humans; Hydrazones; Hypertension, Pulmonary; Intensive Care Units; Male; Myocardial Infarction; Prognosis; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Vascular Resistance; Ventricular Dysfunction, Right | 2010 |
Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?
Topics: Acute Disease; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2010 |
Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pilot Projects; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Pyridazines; Respiration; Respiration, Artificial; Simendan; Ventilator Weaning; Ventricular Dysfunction, Left | 2011 |
Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Topics: Adolescent; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Male; Milrinone; Pyridazines; Retrospective Studies; Simendan; Treatment Outcome | 2011 |
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea | 2010 |
Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2010 |
How to treat acute decompensated heart failure in the 'beta-blocker era'?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Vasodilator Agents | 2010 |
Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
Topics: Aged; Atrial Function, Left; Biomarkers; Chronic Disease; Dobutamine; Echocardiography; Echocardiography, Stress; Female; Forecasting; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Treatment Outcome | 2012 |
[Treatment of heart failure patients with inotropic drugs: beyond traditional agents].
Topics: Adrenergic beta-1 Receptor Agonists; Cardiotonic Agents; Dobutamine; Guidelines as Topic; Heart Failure; Hydrazones; Meta-Analysis as Topic; Phosphodiesterase Inhibitors; Pyridazines; Retrospective Studies; Risk Assessment; Simendan | 2010 |
Cost-effectiveness of levosimendan in patients with acute heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Patient Readmission; Pyridazines; Retrospective Studies; Simendan; Survival Rate | 2011 |
Prevention for pediatric low cardiac output syndrome: results from the European survey EuLoCOS-Paed.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Child, Preschool; Dobutamine; Dopamine; Drug Therapy, Combination; Epinephrine; Europe; Health Care Surveys; Hospitals; Humans; Hydrazones; Infant; Milrinone; Pediatrics; Practice Patterns, Physicians'; Pyridazines; Simendan; Surveys and Questionnaires | 2011 |
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; Hydrazones; Male; Milrinone; Pyridazines; Simendan | 2011 |
Pharmacologic interventions to improve splanchnic oxygenation during ventilation with positive end-expiratory pressure.
Topics: Anesthesia, Epidural; Dobutamine; Dopamine; Humans; Hydrazones; Milrinone; Oxygen; Oxygen Consumption; Oxyhemoglobins; Positive-Pressure Respiration; Pulmonary Ventilation; Pyridazines; Receptors, Catecholamine; Simendan; Splanchnic Circulation; Vital Capacity | 2012 |
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.
Topics: Acute Disease; Aged; Alkaline Phosphatase; Cardiotonic Agents; Cholestasis; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Liver Diseases; Liver Function Tests; Male; Prognosis; Prospective Studies; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Transaminases | 2013 |
Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Topics: Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Heart Failure; Hospitalization; Humans; Hydrazones; Pyridazines; Retrospective Studies; Rome; Simendan; Treatment Outcome | 2012 |
Levosimendan: a retrospective single-center case series.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Intensive Care Units; Male; Milrinone; Norepinephrine; Pyridazines; Retrospective Studies; Simendan; Sympathomimetics; Treatment Outcome | 2013 |
Chronic measurement of left ventricular pressure in freely moving rats.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Dobutamine; Heart Rate; Hydrazones; Isoproterenol; Male; Pyridazines; Rats; Rats, Wistar; Simendan; Telemetry; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure; Verapamil | 2013 |
Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Disease Progression; Dobutamine; Female; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Pyridazines; Retrospective Studies; Simendan | 2014 |
[Nitrid oxide, levosimendan and sildenafile in a patient with right ventricle dysfunction and severe pulmonary hypertension after cardiac surgery].
Topics: Aged; Aorta; Dobutamine; Drug Synergism; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Hypertension, Pulmonary; Nitric Oxide; Norepinephrine; Postoperative Complications; Pyridazines; Sildenafil Citrate; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Right | 2014 |
Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Germany; Humans; Hydrazones; Insurance, Health; Length of Stay; Markov Chains; Models, Econometric; Pyridazines; Simendan | 2016 |
Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension.
Topics: Animals; Calcium; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Hemodynamics; Hydrazones; Hypertension, Pulmonary; Male; Milrinone; Pyridazines; Rats; Rats, Wistar; Simendan | 2017 |
Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis.
Topics: Acute Disease; Aged; Cardio-Renal Syndrome; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Incidence; Male; Middle Aged; Pyridazines; Retrospective Studies; Simendan | 2017 |
Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Topics: Adolescent; Adult; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Infant; Infusions, Intravenous; Male; Milrinone; Retrospective Studies; Simendan; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Treatments targeting inotropy.
Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholamines; Clinical Trials as Topic; Diastole; Dobutamine; Dogs; Energy Metabolism; Excitation Contraction Coupling; Heart Failure; Humans; Mitochondria; Models, Animal; Myocardial Contraction; Nitrogen Oxides; Oxidation-Reduction; Phosphodiesterase Inhibitors; Placebos; Receptors, Adrenergic; Sarcomeres; Shock, Cardiogenic; Simendan; Swine; Systole; Urea | 2019 |
Reversing Cholinergic Bronchoconstriction by Common Inotropic Agents: A Randomized Experimental Trial on Isolated Perfused Rat Lungs.
Topics: Acetylcholine; Airway Resistance; Animals; Bronchoconstriction; Bronchodilator Agents; Cardiotonic Agents; Cholinergic Agents; Dobutamine; Lung; Male; Organ Culture Techniques; Random Allocation; Rats; Rats, Sprague-Dawley; Simendan | 2019 |
Levosimendan with other inotropes or vasopressors: Should you combine them?
Topics: Acute Disease; Aged; Aged, 80 and over; Arterial Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospital Mortality; Humans; Hypotension; Length of Stay; Male; Middle Aged; Norepinephrine; Simendan; Tachycardia, Supraventricular; Treatment Outcome; Vasoconstrictor Agents | 2020 |
COVID-19 infection in left ventricular assist device patients.
Topics: Aged; Cardiotonic Agents; COVID-19; Dobutamine; Furosemide; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Simendan; Ventricular Dysfunction, Right | 2020 |
Levosimendan or dobutamine in patients with low cardiac output syndrome: Results from meta-analysis.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Dobutamine; Humans; Hydrazones; Pyridazines; Simendan | 2021 |
Reply to: Levosimendan or dobutamine in patients with low cardiac output syndrome: Results from meta-analysis.
Topics: Cardiac Output, Low; Dobutamine; Humans; Hydrazones; Pyridazines; Simendan | 2021 |
Comparison of dobutamine and levosimendan for treatment of sepsis-induced cardiac dysfunction: A protocol for systematic review and meta-analysis.
Topics: Dobutamine; Heart Diseases; Humans; Meta-Analysis as Topic; Sepsis; Simendan; Systematic Reviews as Topic | 2022 |
[Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure].
Topics: Cardiovascular Agents; Cross-Sectional Studies; Dobutamine; Heart Failure; Humans; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Function, Right | 2023 |
Preoperative Levosimendan Administration in Heart Transplant Patients with Severe Hepatic and Renal Impairment: A Retrospective Study.
Topics: Dobutamine; Dopamine; Heart Failure; Heart Transplantation; Humans; Renal Insufficiency; Retrospective Studies; Simendan | 2023 |